Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

Sjögreen Gleisner, Katarina LU ; Chouin, Nicolas ; Gabina, Pablo Minguez LU ; Cicone, Francesco ; Gnesin, Silvano ; Stokke, Caroline ; Konijnenberg, Mark ; Cremonesi, Marta ; Verburg, Frederik A. and Bernhardt, Peter , et al. (2022) In European Journal of Nuclear Medicine and Molecular Imaging 49(6). p.1778-1809
Abstract

The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals labelled with lutetium-177 (177Lu) are increasingly used for therapeutic applications, in particular for the treatment of metastatic neuroendocrine tumours using ligands for somatostatin receptors and prostate adenocarcinoma with small-molecule PSMA-targeting ligands. This paper provides an overview of reported dosimetry data for these therapies and summarises current knowledge about radiation-induced side effects on normal tissues and dose-effect relationships for tumours. Dosimetry methods and data are summarised for kidneys, bone marrow, salivary glands, lacrimal... (More)

The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals labelled with lutetium-177 (177Lu) are increasingly used for therapeutic applications, in particular for the treatment of metastatic neuroendocrine tumours using ligands for somatostatin receptors and prostate adenocarcinoma with small-molecule PSMA-targeting ligands. This paper provides an overview of reported dosimetry data for these therapies and summarises current knowledge about radiation-induced side effects on normal tissues and dose-effect relationships for tumours. Dosimetry methods and data are summarised for kidneys, bone marrow, salivary glands, lacrimal glands, pituitary glands, tumours, and the skin in case of radiopharmaceutical extravasation. Where applicable, taking into account the present status of the field and recent evidence in the literature, guidance is provided. The purpose of these recommendations is to encourage the practice of patient-specific dosimetry in therapy with 177Lu-labelled compounds. The proposed methods should be within the scope of centres offering therapy with 177Lu-labelled ligands for somatostatin receptors or small-molecule PSMA.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Dosimetry, Lutetium-177, Neuroendocrine, Prostate adenocarcinoma, PSMA-targeting ligands, Somatostatin-receptor ligands
in
European Journal of Nuclear Medicine and Molecular Imaging
volume
49
issue
6
pages
32 pages
publisher
Springer
external identifiers
  • scopus:85126133440
  • pmid:35284969
ISSN
1619-7070
DOI
10.1007/s00259-022-05727-7
language
English
LU publication?
yes
id
2fdd9382-d491-4537-8c06-9495c75105b8
date added to LUP
2022-12-27 16:00:06
date last changed
2024-06-15 03:07:55
@article{2fdd9382-d491-4537-8c06-9495c75105b8,
  abstract     = {{<p>The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals labelled with lutetium-177 (177Lu) are increasingly used for therapeutic applications, in particular for the treatment of metastatic neuroendocrine tumours using ligands for somatostatin receptors and prostate adenocarcinoma with small-molecule PSMA-targeting ligands. This paper provides an overview of reported dosimetry data for these therapies and summarises current knowledge about radiation-induced side effects on normal tissues and dose-effect relationships for tumours. Dosimetry methods and data are summarised for kidneys, bone marrow, salivary glands, lacrimal glands, pituitary glands, tumours, and the skin in case of radiopharmaceutical extravasation. Where applicable, taking into account the present status of the field and recent evidence in the literature, guidance is provided. The purpose of these recommendations is to encourage the practice of patient-specific dosimetry in therapy with 177Lu-labelled compounds. The proposed methods should be within the scope of centres offering therapy with 177Lu-labelled ligands for somatostatin receptors or small-molecule PSMA.</p>}},
  author       = {{Sjögreen Gleisner, Katarina and Chouin, Nicolas and Gabina, Pablo Minguez and Cicone, Francesco and Gnesin, Silvano and Stokke, Caroline and Konijnenberg, Mark and Cremonesi, Marta and Verburg, Frederik A. and Bernhardt, Peter and Eberlein, Uta and Gear, Jonathan}},
  issn         = {{1619-7070}},
  keywords     = {{Dosimetry; Lutetium-177; Neuroendocrine; Prostate adenocarcinoma; PSMA-targeting ligands; Somatostatin-receptor ligands}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{1778--1809}},
  publisher    = {{Springer}},
  series       = {{European Journal of Nuclear Medicine and Molecular Imaging}},
  title        = {{EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands}},
  url          = {{http://dx.doi.org/10.1007/s00259-022-05727-7}},
  doi          = {{10.1007/s00259-022-05727-7}},
  volume       = {{49}},
  year         = {{2022}},
}